Merck KGaA
5-year stock timeline
Merck KGaA (XETRA: MRK) — latest price 129.5 — concise factual 5‑year timeline and the material drivers below.
Five‑year timeline
2020: The group weathered the COVID shock and reported strong fiscal 2020 results with sales up ~8.6% to €17.5bn and improved EBITDA-pre margin. The Performance Materials division was renamed Electronics as part of structural reorganization.
2020–2021: Clinical and regulatory progress accelerated the recovery. Tepotinib approvals and the global roll‑out of Mavenclad drove revenue growth as COVID impacts eased.
2021–2026: Leadership and go‑to‑market strategy shifted materially. Belén Garijo became Chair and CEO in May 2021, driving initiatives including expanded market models such as Africa go‑to‑market efforts. A succession to Kai Beckmann was announced in 2025, effective May 2026.
Events that moved the stock
Pandemic shock and operational resilience: The March–mid‑2020 market dislocation followed by stronger‑than‑expected FY2020 results created significant near‑term sentiment catalysts.
Clinical and regulatory readouts: Discrete positive re‑rating moments came from product launches and label progress in oncology and MS franchises, particularly when uptake beat expectations.
Corporate actions and leadership changes: Targeted M&A and portfolio moves, the 2021 CEO appointment, and the 2025/26 succession announcement repeatedly shifted investor focus between growth execution and management stewardship.
Investor perception and narrative
Early 2020: Viewed as a diversified, defensive compounder—a mix of Healthcare, Life Science and Electronics exposure that proved resilient during COVID.
2021–2023: The narrative shifted toward selective growth and innovation as new drug launches and life‑science momentum promised revenue inflection.
2024–2026: Focus moved to execution and leadership continuity, with investors scrutinizing capital allocation around the announced CEO transition.
Key technical phases
Pandemic drawdown and recovery: Sharp volatility in early‑2020 followed by sustained recovery through late‑2020 and into 2021, tracking operational rebound and positive corporate news.
Rotation and consolidation 2022–2023: Periods of sideways consolidation and relative underperformance amid macro uncertainty, with breakouts aligned to biotech updates and re‑rating moves around the 2021 management change and the 2025 succession announcement.
If a concise year‑by‑year event table or annotated price chart (with 129.5 as current reference) would be useful, let me know your preferred timeframe.
Key risks and downside factors
Merck KGaA runs three separate operations: Life Science, Healthcare, and Electronics. The company competes against scaled players across each segment—large pharma names like Roche, Novartis and Pfizer in Healthcare; life-science tools giants such as Thermo Fisher and Danaher in Life Science, where M&A activity and sheer scale create persistent pressure; and specialty materials firms in Electronics. That breadth means product risk and regulatory risk are baked into the model across multiple fronts.
- Larger life-science and CDMO players like Thermo Fisher and Danaher are well-positioned to compete aggressively, which could put real pressure on pricing and margins[4][1].
- Regulatory hurdles, approval timelines, and patent expirations pose real risk to the Healthcare segment's drug sales and pipeline valuation.
- The Electronics materials market's cyclical nature and concentrated customer base create real revenue exposure when semiconductor and display cycles turn, particularly as consolidation continues reshaping the industry.
- Supply-chain disruptions, raw-material volatility, and integration challenges from M&A activity could pressure margins and execution across the board, particularly as competition intensifies around scale.
Competitive landscape
Merck KGaA operates across Healthcare, Life Science, and Electronics—a sprawl that puts it in direct competition with integrated pharmaceutical groups like Roche (RO.SIX, ISIN CH0012032113) and Bayer (BAYN.TRADEGATE, ISIN DE000BAY0017), alongside specialized suppliers in life-science tools and materials. The competitive landscape is dense: large pharma rivals squeeze margins, specialized instrument makers nibble at specific segments, and cyclical swings in electronics materials demand keep pressure constant. For Merck, this translates to relentless R&D spending, pricing headwinds, and the perpetual supply-chain tightening that comes with operating at scale across three distinct markets.
| Company | Ticker |
|---|---|
| Roche Holding AG | RO.SIX |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialPerformance Figures of Merck KGaA
Relative Performance vs Benchmarks
| Period | Merck KGaA | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +16.20% | +11.94% | +10.75% |
| 3M | +2.96% | +3.92% | -6.74% |
| 6M | +13.88% | +8.82% | +3.44% |
| 1Y | +14.52% | +10.34% | -14.63% |
| 3Y | -17.24% | -74.22% | -102.91% |
| 5Y | -5.22% | -66.58% | -96.52% |
Get More Stock Analyses Like This
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHistorical valuation trends
How the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 22.2 | 2.7 | 1.9 | 13.4 |
| 1Y ago | 18.1 | 2.4 | 1.7 | 12.4 |
| 3Y ago | 22.2 | 3.2 | 2.7 | 16.8 |
| 5Y ago | 27.6 | 3.5 | 3.3 | 15.1 |
Frequently Asked Questions
Where is the Merck KGaA stock traded?
What does Merck KGaA do?
What are the key metrics for MRK.XETRA?
How has Merck KGaA's stock price performed?
How is MRK.XETRA valued?
Does MRK.XETRA pay dividends?
What are the key risks when investing in MRK.XETRA?
- Larger life-science and CDMO players like Thermo Fisher and Danaher are well-positioned to compete aggressively, which could put real pressure on pricing and margins[web:4][web:1].
- Regulatory hurdles, approval timelines, and patent expirations pose real risk to the Healthcare segment's drug sales and pipeline valuation.
- The Electronics materials market's cyclical nature and concentrated customer base create real revenue exposure when semiconductor and display cycles turn, particularly as consolidation continues reshaping the industry.
- Supply-chain disruptions, raw-material volatility, and integration challenges from M&A activity could pressure margins and execution across the board, particularly as competition intensifies around scale.
Who are the main competitors of Merck KGaA?
- Roche Holding AG (RO.SIX)
When does Merck KGaA report earnings?
Key Metrics
Valuation Metrics
Profitability Metrics
Growth Metrics
Dividend history
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 2.20 EUR | 1.97% | 1.35% |
| 2025 | 2.20 EUR | 1.82% | |
| 2024 | 2.20 EUR | 1.45% | |
| 2023 | 2.20 EUR | 1.35% | |
| 2022 | 1.85 EUR | 1.05% | |
| 2021 | 1.40 EUR | 0.97% | |
| 2020 | 1.30 EUR | 1.23% | |
| 2020 | 1.30 EUR | 1.24% | |
| 2019 | 1.25 EUR | 1.31% | |
| 2018 | 1.25 EUR | 1.51% | |
| 2017 | 1.20 EUR | 1.11% | |
| 2016 | 1.05 EUR | 1.28% | |
| 2015 | 1.00 EUR | 0.95% | |
| 2014 | 0.95 EUR | 1.55% | |
| 2013 | 0.85 EUR | 1.46% |
Earnings history & estimates
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Historical earnings performance
Upcoming earnings report
Analyst estimates for upcoming periods
Key financial figures
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 21.10B | 21.16B | 20.99B | 22.23B | 19.69B |
| Operating income (EBIT) | 4.07B | 4.37B | 4.04B | 5.00B | 4.28B |
| Net income | 2.61B | 2.78B | 2.82B | 3.33B | 3.06B |
| Free cash flow | 2.35B | 2.40B | 1.76B | 2.45B | 3.19B |
| Total assets | 52.10B | 51.57B | 48.49B | 48.53B | 45.36B |
| Equity | 28.59B | 29.91B | 26.68B | 25.93B | 21.34B |
| Net debt | 9.23B | 8.12B | 7.96B | 9.00B | 9.26B |
PWP Leeway UG (haftungsbeschränkt)
